nach oben

Erschienen in:

01.06.2019 | Clinical study

Cancer risk evaluated in PsA patients treated with TNFi

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

There appears to be no increased risk of cancer in patients with psoriatic arthritis (PsA) treated with tumour necrosis factor inhibitors (TNFi) versus the general Nordic population, say European researchers. …

Ballegaard C, et al. Incidence of Overall and Site-Specific Cancers in Tnf Inhibitor Treated Patients with Psoriatic Arthritis: a Population-Based Cohort Study from 4 Nordic Countries. 20th Annual Congress of the European League Against Rheumatism : abstr. OP0005, 12 Jun 2019. Available from: URL: http://scientific.sparx-ip.net/archiveeular/index.cfm?c=a&view=2&item=2019OP0005

Titel: Cancer risk evaluated in PsA patients treated with TNFi
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63894-8

Adenovirus-vaccine/listeria-monocytogenes-vaccine

Case report

Capecitabine/carboplatin

Case report

Hydroxychloroquine

Case report

Aripiprazole/valbenazine

Case report

Antifungals/cytokines

Case report

Hydroxyzine

Case report

Springer Medizin

Cancer risk evaluated in PsA patients treated with TNFi

Excerpt

Weitere Artikel der Ausgabe 1/2019

Adenovirus-vaccine/listeria-monocytogenes-vaccine

Capecitabine/carboplatin

Hydroxychloroquine

Aripiprazole/valbenazine

Antifungals/cytokines

Hydroxyzine

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Adenovirus-vaccine/listeria-monocytogenes-vaccine

Capecitabine/carboplatin

Hydroxychloroquine

Aripiprazole/valbenazine

Antifungals/cytokines

Hydroxyzine